

Individuals with fibromyalgia have a different gait pattern and a reduced walk functional capacity: A systematic review with meta-analysis

Elio Carrasco-Vega^{1,2}; María Ruiz-Muñoz^{1,2,*}; Antonio I. Cuesta-Vargas^{1,2}; Rita Romero-Galisteo^{1, 2}; Manuel Gonzalez-Sanchez^{1,2}

¹ Department of Physiotherapy, Faculty of Health Sciences, University of Málaga, 29071 Málaga, Spain

² Institute of Biomedicine of Málaga (IBIMA), 29010 Málaga, Spain

³ Department of Nursing and Podiatry, Faculty of Health Sciences, University of Málaga, 29071 Málaga, Spain

Corresponding Author:

Maria Ruiz-Muñoz, PhD

University of Málaga, Faculty of Health Sciences,

Arquitecto Francisco Peñalosa, 3, 29071 Málaga, Spain

Email address: marumu@uma.es

Abstract

Background. The aim of the present study was to perform a systematic review and meta-analysis comparing walking test performance and gait pattern between individuals with and without fibromyalgia.

Methodology. This systematic review was registered in PROSPERO with the following reference: CRD42018116200. The search for the scientific articles in this systematic review was carried out using the MEDLINE, SCOPUS, PEDRO, CINHAL and WEB OF SCIENCE databases. A combination of three conceptual groups of terms was used: (1) fibromyalgia;

(2) walk (performance) tests; and (3) gait analysis, linked by the Boolean connectors "AND",

"OR". The obtained articles were analyzed for both functional and pattern of walking data of patients with fibromyalgia. In order to provide a better estimate of the difference between

Formatted: Strikethrough

Commented [GS(1): No need in the abstract

Commented [GS(2): included

Formatted: Strikethrough

34 individuals with and without FM on gait, a meta-analysis was performed on the 6MWT (6-
35 minute walk test).

36 **Results.** Thirty-six studies were analyzed, with a total population of 4,078 participants
37 (3,369 FM and 709 controls). From a functional point of view, the 6MWT distance covered by
38 the group of without FM was significantly greater than that of the individuals
39 with FM in all the analyzed studies. In addition, when comparing the results obtained in the
40 gait pattern analysis, it was observed that
41 individuals with FM walked slower with a shorter stride
42 length, and lower cadence compare to individuals without FM.

43 **Conclusions.** It is possible to affirm that individuals with FM perform walking tests
44 differently than individuals without FM. It has been observed that individuals with FM walk
45 performing a cycle of shorter length and lower frequency, producing a slower gait that
46 results in a shorter distance traveled, in the same period of time, with respect to healthy
47 subjects.

Commented [GS(3): 4,078

Commented [GS(4): 3,369

Commented [GS(5): 6MWT

Commented [GS(6): Without FM

Commented [GS(8): Walked slower

Commented [GS(9): individuals without FM

Commented [GS(10): very confusing sentence

48
49

50 Introduction

51 Fibromyalgia (FM) is a syndrome of unknown etiology[1], with a spectrum of symptoms that
52 most commonly include the presence of generalized chronic pain, fatigue, sleep disturbance,
53 mood disturbance and impaired quality of life[2], causing a great impact on basic activities
54 of daily living [1]. After osteoarthritis, fibromyalgia is the second most common
55 rheumatic disorder[3], with 3-5% of the population suffering from FM[4], although,
56 depending on the diagnostic criteria, the prevalence can reach 8%[3]. Therefore, it can
57 become a great burden for patients, families, and society in general. In Spain, it has been
58 calculated that an individual with FM generates an average annual expense of over €5,000
59 compared to people without FM, of which 90% (i.e., €4,500) are due to a loss of
60 productivity[5].

61

62 Although it is not an inflammatory process, it is accompanied by abnormal sensory
63 responses[6], usually expressed as hyperalgesia and/or allodynia[7][8]. Thus, a central

sensitization mechanism has been described in FM[9], causing an amplification of the neural signal in the central nervous system[10], increasing the extension of the receptive field and unusually prolonging the pain even after the nociceptive stimulus disappears[11]. For this reason, one of the main goals of treating people with FM is to address central pain processing dysfunction[12]. Reduced physical performance capacity and levels of independence in [basic activities of daily living](#) should also be taken into account[13], thus improvement in physical capacity has become an equally basic aspect of recovery.

Different studies have shown that patients suffering from FM have a reduced performance in activities of daily living [14-16], which could be due to a decrease in physical capacities such as balance and postural control [17,18], flexibility [19] and/or an increase in fatigue, a loss of strength and muscular endurance or a lower cardiac capacity [20], which could determine a decrease in physical activity and a change towards a more sedentary lifestyle [20].

One of the basic concepts pursued by rehabilitation is function and movement [14]. The step or gait can be considered one of the locomotor gestures with greater clinical relevance [21], as it could be a very determining factor in the person's independence, since coordination, semi-static and dynamic balance, muscular strength, endurance and reaction capacity in the individual's relationship with the environment are integrated in the same gesture [14,20,22].

The walking analysis could be performed from two different points of view: Functional [23] and biomechanical [24]. The walking performance tests are aimed at evaluating the functional capacity of [an individual](#) in that specific task, while the gait pattern analysis breaks down the specific gesture into biomechanical components.

Traditionally, various gait analysis methods have been used from validated tests to analyze the gait function, such as the 6MWT[22,25], the Cooper KH physical running test[26] and the Timed Up and Go test[27], which provide standard information on the individual's ability to walk. Likewise, the implementation of some tests with instruments for kinematic

measurement, such as inertial sensors[28][29], depth cameras[30] and Smartphone inertial sensors[31], allow analyzing the gait pattern.)

Commented [GS(11): great clarification! 😊

In recent years, different systematic reviews have been carried out to analyze the efficacy of different types of interventions in individuals with fibromyalgia to improve their physical and psychological capacities, such as aerobic exercise [32], walking [33], aquatic [34] and resistance exercise [35]. However, to our knowledge, no systematic review has been published to date that collects and analyzes the impairment of gait, in both gait pattern and functional capacity, in the population with FM.

Objective

The aim of the present review was to perform a systematic review and meta-analysis comparing walking test performance and gait pattern between individuals with and without fibromyalgia.)

Commented [GS(12): Very clear!

Methods

Bibliographic search

The present systematic review was conducted according to the guidelines and recommendations of the PRISMA statement on systematic reviews and meta-analyses[36].

The search was performed on August 15th, 2021. This systematic review was registered in PROSPERO with the following reference: CRD42018116200.

The search for the scientific articles in this systematic review was carried out using the MEDLINE, SCOPUS, PEDRO, CINHAI and WEB OF SCIENCE databases.

The keywords used to perform the search were “Fibromyalgia”, “Exercise”, “Gait”, “Gait Analysis”, “Kinematic”, “Walk”, “Walking” and “Walk test”. There was a constant word in all the searches, i.e., “Fibromyalgia”, which was combined by means of the Boolean AND/OR connectors with the rest of the conceptual groups of terms: “walk” and “gait analysis”. The same search sequence was carried out in all the mentioned databases.

Study selection

The article selection was blindly conducted by two researchers (ECV and MRM) with more than ten years of experience. Any discrepancies in the selection of documents were resolved by a third researcher (MGS).

The inclusion criteria for the selection of the studies were: 1) studies published since 2000; 2) studies carried out in patients diagnosed with fibromyalgia; 3) studies carried out in adult patients over 18 years of age; and 4) studies where at least one outcome variable analyzed the gait pattern and functional capacity.

The exclusion criteria were: 1) publications in a language other than English, Spanish, French, Portuguese and Italian; 2) studies carried out in patients with a BMI greater than 35 points; 3) articles in which BMI data are not mentioned; 4) studies carried out in subjects who had undergone surgery at least one year before the study; and 5) studies in which women were pregnant.

Data collection process

In the same way as the selection of the articles, the data collection process was carried out by two independent blinded investigators. We extracted data from each study related to number of participants (% women), anthropometric data (age, height, weight, and BMI) and outcome variables that analyzed the gait pattern and functional capacity (results on gait functional test and/or that analyzed the gait pattern and functional capacity (results on gait functional test and/or gait pattern variables: gait speed, stride length, cadence, swing, stance, single support, and double support).

Quality Assessment

To evaluate the quality of the included studies, the Newcastle-Ottawa modified quality assessment scale (NOS) was used [37]. The NOS is a tool that evaluates eight aspects, distributed in three different dimensions: selection (representativeness of the sample, sample size, non-respondents, ascertainment of the exposure (risk factor)); comparability and outcome (assessment of the outcome; statistical test). Two blinded researchers carried out the evaluation of the different components of the scale.

156

157 Synthesis of results

158 The included articles were analyzed for both gait pattern and functional capacity
159 data on the fly in individuals with FM including any measurements
160 from healthy control groups.

Commented [GS(13)]: Be consistent with what you stated at the beginning of the text.

161 In the case of longitudinal articles, baseline measurements were used, treating the data as if
162 the articles were cross-sectional studies.

163 In order to provide a better estimate of the effects of fibromyalgia on gait, a meta-analysis
164 was performed on the functional capacity variable that most frequently appeared in the
165 literature search, i.e., in this case, the total meters traveled after completing the 6MWT. A
166 total of 29 studies were integrated into the analysis. To analyze the heterogeneity of the data
167 extracted from the included studies, the 95% prediction interval was calculated. In addition,
168 the effect size were calculated.

Commented [GS(14)]: How did you perform the meta-analysis? It is missing the description of how this statistical analysis was performed. For example: "Did you use Hedges' g to calculate standardized mean difference (SMD) between individuals with and without FM using the means, standard deviations (SD) and sample sizes of both groups? If the full text did not contain SD, did you calculate SD from the reported standard error or confidence intervals (CI)? Did you use random-effects models with an inverse variance (IV) method to pool the SMD of included studies? Did you calculate the heterogeneity with I-squared (I^2)? Did you estimate publication bias visually by via re-displayed funnel plots? Did you use Duval and Tweedie's Trim and Fill test to estimate the adjusted (or unbiased) pooled SMD? Figure 2 could depict a forest plot with the SMD between individuals with and without FM. You can use the software RevMan (Cochrane) to perform the meta-analysis and create the forest plot. Forest plot should show the SMD with 95% confidence intervals of 6MWT as depicted in this example below: ...

169

170 **Results**

171 Search and selection of studies

172 After searching the different databases and eliminating duplicates, a total of 1,481 studies
173 were found, of which 374 were excluded (163 were not conducted in humans and 211 were
174 beyond the established publication date limit), leaving a total of 1,107 articles for screening.
175 Subsequently, 888 were excluded after reading the title and the abstract, since their context
176 was not in accordance with the objectives of the research. The remaining 219 articles were
177 analyzed in full text, of which 184 were discarded. A total of 36 articles were included in the
178 final analysis. For more details about the selection of studies, please refer to Figure 1.

Commented [GS(15)]: 1,481

Commented [GS(16)]: 1,107

179

180 **Figure 1 Here**

181

182 Study characteristics

183 All selected documents were evaluated using the NOS scale. In this sense, the mean score
184 was 7.9 points, with a range from 3 to 10 (table 1). The included
185 studies assessed the gait pattern and functional capacity of movement through different gait

analysis tests. Thirty-one studies were analyzed, with a total population of 4,078 participants (3,369 FM and 709 controls). The vast majority of total participants were women (4,044 women vs 34 men). The highest mean age recorded in the individuals with FM was 56.6 (1.9) years and the lowest was 35.5 (9.9) years. Regarding the control group, the highest mean was 54.1 (4.4) years, and the lowest was 38.7 (7.3) years.

The gait was analyzed both from its pattern and from the functional capacity point of view. The six-minute walk test[38] and the 8-Foot Up and Go (8UG) test[39] were used for the functional capacity analysis. Other authors analyzed the kinematic patterns by free-walking through a walkway or walkways, and with electronic devices such as motion sensors, accelerometers or depth cameras.

The population characteristics and results were grouped in 4 tables. Table 2 shows the population characteristics of the studies that analyzed the gait pattern and the tests used to obtain the data. The kinematic data and the system used for their preparation are summarized in Table 3. The following tables present the population data of the studies that analyzed the amount of walking and the results of the tests.

Analysis from the walk functional capacity point of view

The most used test among the analyzed studies was the 6MWT[38], which was used in a total of 29 studies. The number of participants ranged between 6[56] and 737[61], with an exclusively female sample in all cases, except in the studies of Carbonell-Baeza A et al[56], where the six participants were male, and Giannotti et al[63], where 6.25% of the sample were men. The mean age of the participants ranged from 33.3 (7.4)[50] to 55.9 (1.7) years[71]. The body mass index ranged between 23.4 (4.2)[63] and 29.7 (1.1)[71] in individuals with FM, while in the control group it ranged between 24.2 (3.8)[52] and 28.40 (3.89)[65].

Table 2 presents the characteristics and results of the studies that used the 6MWT as a walk functional capacity test.

Table 2 Here

Of all the studies included in this SR, nine of them compared individuals with and without FM, observing significant differences in the total distance walked between both groups. For the FM group, the shortest distance traveled in the 6MWT test was 300.9 (52.3) meters [48], whereas for the control group it was 373.9 (50.5) meters [48]. Similarly, the greatest distance covered by the FM group was 570.7 (51.9)[765] meters and 656.9 (60.1) meters [62] by the control group. The effect size observed when the values of both groups are compared (individuals with versus without FM) was *Cohen's d*: -1.414 (effect-size *r*: -0.578). Other studies were included, in which the analyzed sample consisted only of individuals with FM, who, in some cases, were grouped into different intervention subgroups. As was previously mentioned, only baseline measurements prior to any intervention were used. Figure 2 shows all mean values and their corresponding standard deviations.

Figure 2 Here

The diagram shows that the results of the healthy subgroups are greater than the majority of the results of the FM subgroups. Only the study of Akkaya[48] obtained a significantly lower result in the healthy subgroup, although the result is significantly higher compared to the FM subgroup of the same study.

Another test used to analyze the walk functional capacity was the "8 foot up and go test"[39], specifically in six of the analyzed studies (Table 3). Of these six studies, the only one that made a comparison between individuals with and without FM is the study of Aparicio V et al[50], with a total sample of 737 subjects (FM: 487/Control group: 250 people). Significant differences were obtained in the execution time of the 8UG Test (FM: 7.02 (2.34) seconds vs Control group: 5.27 (1.03) seconds) (Table 4). In a complementary way, it was observed that the best score for the FM group was 6.8 (1.1) seconds [56], whereas the worst score was 8.35 (2.32) seconds[46]. A subgroup of FM participants in the study of Carbonell-Baeza A et al[44] obtained the worst recorded result, with 8.5 (0.4) seconds. The data are presented in detail in Table 3.

Commented [GS(18)]: It is important to have all the information of the meta-analysis. See comments on the statistical analysis (methods) above

Commented [GS(19)]: Very confusion sentence

Commented [GS(20)]: Very confusion paragraph. This paragraph should summarized the results from the 6MWT meta-analysis (see comment on the statistical analysis (methods) above.

Commented [GS(21)]: Please keep it consistent.

Commented [GS(22)]: What are these FM sub-groups? What is the purpose of having these results here when you consider the objective of this systematic review?

Table 3 Here

Analysis from a gait pattern point of view

Of the 36 studies included in this SR, 7 studies assessed the gait pattern of individuals with fibromyalgia using specific tests and measurement instruments. The use of instruments such as inertial sensors has been validated with individuals with fibromyalgia as an effective reference value[40]. The characteristics of the gait pattern studies are summarized in Table 4.

Table 4 Here

Most of the studies obtained the kinematic data by means of a “Walking speed test” (authors determined a short distance to walk and then they calculated the speed) [41-45], whereas others obtained such data using the 6MWT[46]. In some studies, the distance was not established or described for the production of the kinematic parameters, using free walking while the individuals’ walking patterns were analyzed. The maximum distance described for the kinematic analysis was 18.6 meters [42-44], whereas the minimum was 10 meters[47]. The results of the tests are summarized in Table 4. As can be observed in all the results, the speed (m/s) was lower in the fibromyalgia group than in the control group. The highest speed obtained in the FM group was 1.94 (0.27) m/s[46], compared to 2.18 (0.34) m/s[46] for the control group. The lowest speed was 0.88 (0.2) m/s[45] for the FM group and 1.12 (0.3)[45] for the control group. (

Discussion

The aim of the present study was to carry out a systematic review to verify the impairment in the gait of individuals with fibromyalgia, from a gait pattern and functional capacity point of view. The kinematic variables, as well as the results of the different gait tests analyzed, show that individuals with fibromyalgia have an altered gait pattern and walk less than individuals without FM.

Walk Functional capacity analysis

Commented [GS(23)]: A meta-analysis may be possible when you have more than 2 studies with the same outcome (e. g. Stride Length (m); Cadence (step/min); Swing (%cycle); Stance (%cycle); Single support (%cycle); Double support (%cycle)) and using same (or similar) methods to evaluation (e.g. 18.6m walkway - GAITRite system).

Commented [GS(24)]: I could not find the speed values in table 4.

Commented [GS(25)]: Keep it consistent

280 One of the most widely used tests to analyze the functional capacity was the six-minute walk
281 test (6MWT), which measures the distance that a person walks for 6 minutes[38]. The use of
282 the 6MWT has been recommended both in research and in the clinical setting to carry out a
283 prior assessment or monitoring of the progression of the patient during a treatment on
284 individuals with fibromyalgia [88].

285 Specifically, of the 29 studies included in this SR that used 6MWT, only 9 of them made a
286 comparison between individuals with and without fibromyalgia[46][48-
287 50][59][62][65][74][76], observing that the distance covered by the control group
288 was significantly greater than that of the FM group in all studies. In fact, it was
289 observed that the effect size when comparing both groups was Cohen's d: -1.414 (effect-size
290 r: -0.578). If the usual stratification on the effect size is considered (d = 0.2 small; 0.5
291 medium; 0.8 large [89]), it could be stated that the fibromyalgia condition affects
292 the functional capacity of individuals with FM. Specifically, the differences observed between
293 the control and FM groups after performing the 6MWT range between 68.23m[65]
294 and 105.5m[62]. There could be several causes that justify the differences observed between
295 the two groups. On the one hand, the gait speed of individuals with fibromyalgia
296 is altered compared to a control group, as a consequence of a reduction in both the
297 stride length and the frequency in the gait cycle[90]. On the other hand, the resistance
298 observed in individuals with fibromyalgia when carrying out efforts of medium/long
299 duration is decreased compared to individuals without FM[91]. Therefore,
300 a lower walking speed, added to a lower resistance in moderate efforts, could be at the base
301 of the differences observed between groups.

302 . A possible explanation for the observed data can be found in
303 the fact that the muscle recruitment pattern of individuals with fibromyalgia rather
304 resembles the fast gait pattern (poorly economical and highly energy-consuming) of
305 individuals without FM. This pattern is determined by greater activation of the hip
306 flexors to the detriment of the plantar flexors of the foot/ankle [92]. However, this study
307 identifies a gait pattern with similar characteristics between individuals with and without
308 FM, which is not consistent with the results observed in the present
309 study. In this sense, it would be interesting to design future studies that analyze whether a
310 neuromotor re-education / retraining of individuals with fibromyalgia could improve the

Commented [GS(27): This 9 studies can be included in the meta-analysis (see comment on statistical analysis (methods) above.

Commented [GS(28): This is where you should use results from the meta-analysis and add more information from the studies that could not be included in the meta-analysis but contribute to the discussion around the 6MWT

walk functional capacity and reduce the differences observed in the present study.

Taking as a reference value the distance of 554.5m (53.29) for individuals without FM performing the 6MWT of the Enright PL study[38], the results obtained in the 29 studies (Figure 1) show that three control subgroups totally exceeded this mark, five control subgroups walked distances similar to Enright's mark, and the control subgroup of one study reached a significantly shorter distance. Regarding the FM subgroups, none exceeded this mark, and only one study shows a mean value slightly higher than this mark.

An improvement in the qualitative characteristics of the gait pattern (speed, frequency, and stride length) with a previously designed protocol could improve the functional capacity outcome variables, as has already been demonstrated in other population profiles. In the study of Kaleth A et al[93], the administration of an exercise protocol with 187 patients showed that, at the beginning of the study, the patients were able to walk, in the 6MWT, 482.9 (80.5) meters, after 12 weeks of intervention they could walk 510.8 (84.4) meters, and in 36 weeks they could walk 517.7 (80.9) meters, with a mean change of 34.4 (65.2) meters ($P < 0.001$), which is very close to Enright's mark[38].

As was previously mentioned, future studies designed to improve the symptoms and functional capacities of individuals with fibromyalgia should take into account the aspects presented in this systematic review.

The 8 foot up and go test has also been frequently used to quantify the degree of involvement in individuals with fibromyalgia (Table 3). The results observed in this test are consistent with those obtained with the 6MWT. Once again, a walk functional capacity alteration was observed, which could be due to the alteration of the qualitative characteristics of the sample, showing in some studies that individuals with FM aged 50-60 years achieved results comparable to those observed in individuals without FM aged 80-90 years[39]. This pattern alteration is likely to be identified by different functional gait tests used with individuals with FM.

Gait pattern analysis

Regarding the gait pattern analysis, Table 4 shows lower results in all the comparisons of the kinematic variables for the individuals with FM compared to the control population. When

Commented [GS(29): Not sure about what this would mean.

342 comparing the results obtained in the gait pattern analysis between individuals with
343 fibromyalgia and healthy subjects, it is observed that individuals with FM moved
344 significantly more slowly, with a stride length and cadence lower than that of healthy
345 subjects (Table 4). However, in other characteristics that are used for the gait pattern, such
346 as the percentage of time used in monopodal and bipodal support or rocking, they do not
347 present significant differences (Table 4). A possible explanation for these results can be
348 found in the fact that patients suffering from fibromyalgia have less mobility in the subtalar
349 joint, which affects the plantar/dorsal flexion of the foot, increasing the dynamic imbalance
350 of the patient and the risk of falls in these patients[41][77]. This indicates that patients with
351 fibromyalgia, before this self-perceived instability, preventively reduce the length and
352 cadence of their gait in order to maintain the control of the movement. This reduction in the
353 biomechanical characteristics of gait is similar to that observed in the elderly[39]. Góes S et
354 al[78] showed that middle-aged women with fibromyalgia have a gait pattern similar to that
355 of older women, characterized by reduced ROM of the lower extremities, stride length and
356 speed gait, thus it could be affirmed that patients with fibromyalgia suffer an adaptation in
357 biomechanics similar to that which occurs in aging[39].

358 Moreover, patients suffering from fibromyalgia could be conditioned by psychological
359 factors that could be negatively affecting the cortical and sub-cortical mechanisms of gait
360 control, by sharing the cognitive functions involved in chronic pain[79]. The most obvious
361 result of this conditioned perception of pain is fear of movement or kinesiophobia, which has
362 been correlated in previous studies with an alteration in normal functional movement
363 patterns[80]. Despite the fact that a SR published in 2012 associated, in individuals with
364 fibromyalgia, a perception of fatigue during the execution of the 6MWT with a reduction in
365 the general state of health measured with SF-12[79], other studies have correlated
366 kinesiophobia with walk functional capacity analysis in individuals with fibromyalgia. The
367 importance of cognitive impairment in walking is reinforced in the study of Lundin-Olsson
368 L[81], who analyzed how frail or cognitively disabled older people could not walk while
369 performing a secondary task such as speaking, which is in line with the results obtained in
370 patients with similar involvement[82].

371 In parallel, a walking speed of ≤ 0.8 m/s has been associated with “low physical
372 performance”[83][84]. However, despite the fact that a decrease in gait pattern has been

373 observed in individuals with fibromyalgia, only the study published by Koca I et al. [45]
374 presents a walking speed close to the indicated threshold. It may be necessary to redefine
375 the concept of “low physical performance”, since all the studies analyzed in the present SR
376 show a biomechanical deficit during ambulation. The value of 0.8m/s has been used as a
377 predictive factor of mortality in different population groups [85-87], although, based on the
378 results observed in this SR, “low physical performances” can be identified in values above
379 the aforementioned threshold. Nevertheless, it is important to clarify that this reference
380 value is preferably used in older people, thus there is rather a decrease of functional capacity
381 in individuals with FM, with a decrease in functional capacities, with respect to normality,
382 being frequently associated with problems of different types.

383 Only one study compares the gait pattern in similar population groups of different sex, i.e.,
384 the study of Heredia-Jimenez J et al. [43] which was conducted in men only (N = 26); the
385 results of men with fibromyalgia (n=12) were slightly higher than the rest of the data
386 obtained from the female population, with a speed of 1.16 (0.20) m/s for males with FM,
387 which was also higher than that of the healthy male population, with 1.45 (0.19) m/s. In this
388 sense, it would be necessary to design new studies to identify eventual differences in the gait
389 pattern and / or walk functional capacity between sexes, so that they are taken into account
390 when assessing and monitoring individuals with FM.

391 Other studies have shown a decrease in functional capacities and an alteration in the correct
392 execution of the gait pattern when individuals are forced to perform cognitive tasks during
393 the execution of the gait [94,95]. The literature has identified that individuals with FM have
394 a specific cognitive problem that could be at the base of a worse functional performance [96].
395 It would be interesting in the future to design studies comparing basic functional abilities,
396 such as walking, between individuals with FM and healthy people carrying out dual tasks
397 during the different tests, to analyze whether the results are comparable between both
398 studies. In the same way, the affectation suffered by individuals with FM could be analyzed
399 when they perform functional tasks such as walking, while simultaneously performing
400 cognitive tasks.

401 Furthermore, it is important to bear in mind that different studies have identified deficits in
402 static and dynamic balance in individuals with FM [97,98], and this imbalance could be
403 associated with a greater risk of falling [97,99]. These aspects could justify the alteration in

the gait pattern that causes the individual with FM to perform a more conservative ambulation to minimize the risk of falling.

In addition, on those documents that include patients with a BMI greater than 30kg/m² but less than 35 (exclusion criterion), it should be considered that some alterations identified in the gait may be due to the BMI, thus it would be advisable to interpret these results cautiously.

Strengths and weaknesses

Although this study is the first to analyze and integrate the gait pattern with functional gait abilities in individuals with FM, some weaknesses have been identified that should be taken into account when interpreting the results. Although a bibliographic search was carried out in 5 different databases, there could be relevant documents published in other databases. In the same way, although the documents published in 5 languages were selected, there could be documents published in other languages that were not included in the present study. Finally, it is important to consider that the score of the various selected studies, using the NOS scale, present a medium-high valuation, with few studies obtaining the maximum score and some studies showing a poor score.

Conclusions

Individuals with fibromyalgia have lower functional gait performance and an altered gait pattern compared to healthy subjects. The different movement pattern could generate a lower functional efficiency, thus it would be necessary to investigate whether neuromotor re-education in individuals with FM would imply a recovery of the walk functional capacity, reaching the levels of healthy subjects.

Financing and Conflict of Interest

The authors declare that there are no conflicts of interest in this study.

Commented [GS(30)]: If that is possible, why not include the possible one? Otherwise, I would not have this aspect as a limitation of the study.

Commented [GS(31)]: Agree.

Commented [GS(32)]: This is not a limitation of your systematic review; this is part of your findings. Be careful to not assume individual study limitation to the review's limitations. The quality assessment has the purpose of flags methodological flaws (if any) of the included studies)

Commented [GS(33)]: Why only neuromotor re-education? This can be one of a number of non-pharmacological interventions that could bring benefits to the walking performance of individuals with FM.

Commented [GS(34)]: Conclusion should focus on the systematic review as a whole (considering results from meta-analysis; qualitative and descriptive analysis were performed; and quality assessment of the included studies. A conclusion example from a Cochrane review, in which all the above elements of the systematic review findings are used to draw these final considerations (<https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013340/full>): "Compared to control, moderate-quality evidence indicates that mixed exercise probably improves HRQL, physical function, and fatigue, but this improvement may be small and clinically unimportant for some participants; physical function shows improvement in all participants. Withdrawal was similar across groups. Low-quality evidence suggests that mixed exercise may slightly improve stiffness. Very low-quality evidence indicates that we are 'uncertain' whether the long-term effects of mixed exercise are maintained for all outcomes; all-cause withdrawals and adverse events were not measured. Compared to other exercise or non-exercise interventions, we are uncertain about the effects of mixed exercise because we found only very low-quality evidence obtained from small, very heterogeneous trials. Although mixed exercise appears to be well tolerated (similar withdrawal rates across groups), evidence on adverse events is scarce, so we are uncertain about its safety. We downgraded the evidence from these trials due to imprecision (small trials), selection bias (e.g. allocation), blinding of participants and care providers or outcome assessors, and selective reporting."

References

1. Harris R. Newer treatments for fibromyalgia syndrome. *Therapeutics and Clinical Risk Management*. 2008;Volume4:1331-1342.
2. Sumpton J, Moulin D. Fibromyalgia. *Handbook of Clinical Neurology*. 2014;:513-527.
3. Clauw D. Fibromyalgia. *JAMA*. 2014;311(15):1547.
4. Okifuji A, Gao J, Bokar C, Hare B. Management of fibromyalgia syndrome in 2016. *Pain Management*. 2016;6(4):383-400.
5. Sicras A, Rejas J, Navarro R, Blanca M, Morcillo A, Larios R et al. Treating patients with fibromyalgia in primary care settings under routine medical practice: a claim database cost and burden of illness study. *Arthritis Research & Therapy*. 2009;11(2):R54.
6. Williams D, Clauw D. Understanding Fibromyalgia: Lessons from the Broader Pain Research Community. *The Journal of Pain*. 2009;10(8):777-791.
7. Jon Russell I. Advances in Fibromyalgia: Possible Role for Central Neurochemicals. *The American Journal of the Medical Sciences*. 1998;315(6):377-384.
8. Carville S, Choy E. Systematic Review of Discriminating Power of Outcome Measures Used in Clinical Trials of Fibromyalgia. *The Journal of Rheumatology*. 2008;35(11):2094-2105.
9. Cuesta-Vargas A, Neblett R, Chiarotto A, Kregel J, Nijs J, van Wilgen C et al. Dimensionality and Reliability of the Central Sensitization Inventory in a Pooled Multicountry Sample. *The Journal of Pain*. 2018;19(3):317-329.
10. Yunus MB. Central sensitivity syndromes: A unified concept for fibromyalgia and other similar maladies. *Journal of Indian Rheumatology Association*. 2000;8:27-33.
11. Mayer, T., Neblett, R., Cohen, H., Howard, K., Choi, Y., & Williams, M. et al. The Development and Psychometric Validation of the Central Sensitization Inventory. *Pain Practice*, 2011. 12(4), 276-285.
12. Sumpton J, Moulin D. Fibromyalgia. *Handbook of Clinical Neurology*. 2014;513-527.
13. García-Hermoso A, Saavedra J, Escalante Y. Effects of exercise on functional aerobic capacity in adults with fibromyalgia syndrome: A systematic review of randomized controlled trials. *Journal of Back and Musculoskeletal Rehabilitation*. 2015;28(4):609-619.
14. Bravo C, Skjaerven LV, Sein-Echaluce LG, Catalan-Matamoros D. Effectiveness of movement and body awareness therapies in patients with fibromyalgia: a systematic review and meta-analysis. *Eur J Phys Rehabil Med*. 2019 Oct;55(5):646-657. doi: 10.23736/S1973-9087.19.05291-2.

15. Da Silva Costa I, Gamundí A, Vivas JG, Souza LG, Novaes C, Montoya P. Altered Functional Performance in Patients with Fibromyalgia. *Front Hum Neurosci*. 2017 Jan 26;11:14. doi: 10.3389/fnhum.2017.00014.
16. Rasouli O, Stensdotter AK, Van der Meer ALH. TauG-guidance of dynamic balance control during gait initiation in patients with chronic fatigue syndrome and fibromyalgia. *Clin Biomech (Bristol, Avon)*. 2016 Aug;37:147-152. doi: 10.1016/j.clinbiomech.2016.07.008.
17. Garrido-Ardila EM, González-Lopez-Arza MV, Jiménez-Palomares M, et al. Effectiveness of acupuncture vs. core stability training in balance and functional capacity of women with fibromyalgia: a randomized controlled trial. *Clin Rehabil*. 2020;34(5):630-645.
18. Muto LHA, Sauer JF, Yuan SLK, Sousa A, Mango PC, Marques AP. Postural control and balance self-efficacy in women with fibromyalgia: are there differences? *Eur J Phys Rehabil Med*. 2015 Apr;51(2):149-54.
19. Kim SK, Busch AJ, Overend TJ, Schachter CL, van der Spuy I, Boden C, Góes SM, Foulds H, Bidonde J. Flexibility exercise training for adults with fibromyalgia. *Cochrane Database Syst Rev* 2019 Sep 2;9(9):CD013419. doi: 10.1002/14651858.CD013419.
20. Loftus N, Dobbin N, Crampton JS. The effects of a group exercise and education programme on symptoms and physical fitness in patients with fibromyalgia: a prospective observational cohort study. *Disabil Rehabil*. 2021 Mar 1;1-8. doi: 10.1080/09638288.2021.1891463.
21. Heredia-Jimenez J, Orantes-Gonzalez E. Gender differences in patients with fibromyalgia: a gait analysis. *Clin Rheumatol*. 2019 Feb;38(2):513-522. doi: 10.1007/s10067-018-4293-x.
22. Natvig, Dag Bruusgaard, Willy Eriks B. Physical Leisure Activity Level and Physical Fitness among Women with Fibromyalgia. *Scandinavian Journal of Rheumatology*. 1998;27(5):337-341.
23. Taul-Madsen L, Connolly L, Dennett R, Freeman J, Dalgas U, Hvid LG. Is aerobic or resistance training the most effective exercise modality for improving lower extremity physical function and perceived fatigue in people with multiple sclerosis? A systematic review and meta-analysis. *Arch Phys Med Rehabil*. 2021 Apr 24:S0003-9993(21)00307-5. doi: 10.1016/j.apmr.2021.03.026.
24. Wang J, Ullah S, Solano MA, Overley SC, Bumpass DB, Mannen EM. Changes in kinematics, kinetics, and muscle activity in patients with lumbar spinal stenosis during gait: systematic review. *Spine J*. 2021 Jun 8:S1529-9430(21)00724-5. doi: 10.1016/j.spinee.2021.06.003.
25. Balke B. A simple field test for the assessment of physical fitness. *Rep Civ Aeromed Res Inst US*. 1963(53):1-8.
26. Cooper KH. A means of assessing maximal oxygen intake: correlation between field and treadmill testing. *JAMA*. 1968; 203 (3): 201-4.

- 502 27. Podsiadlo D, Richardson S. The Timed Up & Go: A test of basic functional mobility for frail elderly
503 persons. *J Am Geriatr Soc* 1991; 39:142-8.
- 504 28. Johnston W, O'Reilly M, Coughlan G, F, Caulfield B, Inertial Sensor Technology Can Capture
505 Changes in Dynamic Balance Control during the Y Balance Test. *Digit Biomark* 2017;1:106-117.
- 506 29. O'Reilly MA, Whelan DF, Ward TE, Delahunt E, Caulfield BM. Classification of deadlift
507 biomechanics with wearable inertial measurement units. *J Biomech.* 2017;58:155-61. doi:
508 10.1016/j.jbiomech.2017.04.028
- 509 30. Moreno F-Á, Merchán-Baeza JA, González-Sánchez M, González-Jiménez J, Cuesta-Vargas AI.
510 Experimental Validation of Depth Cameras for the Parameterization of Functional Balance of
511 Patients in Clinical Tests. *Sensors.* 2017 Feb 22;17(2).
- 512 31. Galán-Mercant A, Barón-López FJ, Labajos-Manzanares MT, Cuesta-Vargas AI. Reliability and
513 criterion-related validity with a smartphone used in timed-up-and-go test. *Biomed Eng Online.*
514 2014 Dec 2;13:156.
- 515 32. Bidonde J, Busch AJ, Schachter CL, Overend TJ, Kim SY, Góes SM, Boden C, Foulds HJ. Aerobic
516 exercise training for adults with fibromyalgia. *Cochrane Database Syst Rev.* 2017 Jun
517 21;6(6):CD012700. doi: 10.1002/14651858.CD012700.
- 518 33. O'Connor SR, Tully MA, Ryan B, Bleakley CM, Baxter GD, Bradley JM, McDonough SM. Walking
519 exercise for chronic musculoskeletal pain: systematic review and meta-analysis. *Arch Phys Med*
520 *Rehabil.* 2015 Apr;96(4):724-734.e3. doi: 10.1016/j.apmr.2014.12.003.
- 521 34. Bidonde J, Busch AJ, Webber SC, Schachter CL, Danyliw A, Overend TJ, Richards RS, Rader T.
522 Aquatic exercise training for fibromyalgia. *Cochrane Database Syst Rev.* 2014 Oct
523 28;(10):CD011336. doi: 10.1002/14651858.CD011336.
- 524 35. Busch AJ, Webber SC, Richards RS, Bidonde J, Schachter CL, Schafer LA, Danyliw A, Sawant A, Dal
525 Bello-Haas V, Rader T, Overend TJ. Resistance exercise training for fibromyalgia. *Cochrane*
526 *Database Syst Rev.* 2013 Dec 20;2013(12):CD010884. doi: 10.1002/14651858.CD010884
- 527 36. Moher D, Liberati A, Tetzlaff J, Altman D. Preferred Reporting Items for Systematic Reviews and
528 Meta-Analyses: The PRISMA Statement. *PLoS Medicine.* 2009;6(7):e1000097.
- 529 37. Modesti PA, Reboldi G, Cappuccio FP, Agyemang C, Remuzzi G, Rapi S, Perruolo E, Parati G, ESH
530 Working Group on CV Risk in Low Resource Settings. Panethnic Differences in Blood Pressure in
531 Europe: A Systematic Review and Meta-Analysis. *PLoS One.* 2016 Jan 25;11(1):e0147601. doi:
532 10.1371/journal.pone.0147601.
- 533 38. Enright PL. The six-minute walk test. *Respir Care.* 2003;48(8):783-785.

534 39. Rikli RE, Jones CJ. Development and validation of a functional fitness test for community-residing
535 older adults. *J Aging Phys Act*. 1999;7(2):129–61.

536 40. Segura-Jimenez V, Munguia-Izquierdo D, Camiletti-Moiron D, Alvarez-Gallardo IC, Ortega FB, Ruiz
537 JR, et al. Comparison of the International Physical Activity Questionnaire (IPAQ) with a multi-
538 sensor armband accelerometer in women with fibromyalgia: the al-Andalus project. *Clin Exp*
539 *Rheumatol*. 2013;31(6-Suppl.79):S94–101.

540 41. Góes S, Leite N, Stefanello J, Homann D, Lynn S, Rodacki A. Ankle dorsiflexion may play an
541 important role in falls in women with fibromyalgia. *Clinical Biomechanics*. 2015;30(6):593-598.

542 42. Heredia Jiménez J, Aparicio García-Molina V, Porres Foulquie J, Delgado Fernández M, Soto
543 Hermoso V. Spatial-temporal parameters of gait in women with fibromyalgia. *Clinical*
544 *Rheumatology*. 2009;28(5):595-598.

545 43. Heredia-Jimenez J, Soto-Hermoso V. Kinematics gait disorder in men with fibromyalgia.
546 *Rheumatology International*. 2013;34(1):63-65.

547 44. Heredia-Jimenez J, Orantes-Gonzalez E, Soto-Hermoso V. Variability of gait, bilateral
548 coordination, and asymmetry in women with fibromyalgia. *Gait & Posture*. 2016;45:41-44.

549 45. Koca I, Savas E, Ozturk Z, Boyaci A, Tutoglu A, Alkan S et al. The evaluation in terms of sarcopenia
550 of patients with fibromyalgia syndrome. *Wiener klinische Wochenschrift*. 2015;128(21-22):816-
551 821.

552 46. Latorre-Román P, Santos-Campos M, Heredia-Jimenez J, et al. Analysis of the performance of
553 women with Fibromyalgia in the six-minute walk test and its relation with health and quality of
554 life. *J Sports Med Phys Fitness* 2014;54:511–7.

555 47. Martín-Martínez J, Villafaina S, Collado-Mateo D, Fuentes-García J, Pérez-Gómez J, Gusi N. Impact
556 of cognitive tasks on biomechanical and kinematic parameters of gait in women with
557 fibromyalgia: A cross-sectional study. *Physiology & Behavior*. 2020;227:113171.

558 48. Akkaya N, Akkaya S, Atalay N, Balci C, Sahin F. Relationship between the body image and level of
559 pain, functional status, severity of depression, and quality of life in patients with fibromyalgia
560 syndrome. *Clinical Rheumatology*. 2012;31(6):983-988.

561 49. Andreissy Breda C, Félix Rodacki A, Leite N, Homann D, Meira Goes S, Facco Stefanello J. Physical
562 activity level and physical performance in the 6-minute walk test in women with fibromyalgia.
563 *Revista Brasileira de Reumatologia (English Edition)*. 2013;53(3):276-281.

564 50. Aparicio V, Segura-jiménez V, Álvarez-gallardo I, Soriano-maldonado A, Castro-piñero J, Delgado-
565 fernández M et al. Fitness Testing in the Fibromyalgia Diagnosis. *Medicine & Science in Sports &*
566 *Exercise*. 2015;47(3):451-459.

- 567 51. Auvinet B, Chaleil D, Cabane J, Dumolard A, Hatron P, Juvin R, Lanteri-Minet M, Mainguy Y, Negre-
568 Pages L, Pillard F, Riviere D, Maugars YM. The interest of gait markers in the identification of
569 subgroups among fibromyalgia patients. *BMC Musculoskelet Disord*. 2011 Nov 11;12:258. doi:
570 10.1186/1471-2474-12-258.
- 571 52. Ayán C, Martín V, Alonso-Cortés B, Álvarez M, Valencia M, Barrientos M. Relationship between
572 aerobic fitness and quality of life in female patients with fibromyalgia. *Clinical Rehabilitation*.
573 2007;21(12):1109-1113.
- 574 53. Carbonell-Baeza A, Aparicio V, Ortega F, Cuevas A, Alvarez I, Ruiz J et al. Does a 3-month
575 multidisciplinary intervention improve pain, body composition and physical fitness in women
576 with fibromyalgia?. *British Journal of Sports Medicine*. 2010;45(15):1189-1195.
- 577 54. Carbonell-Baeza A, Aparicio V, Martins-Pereira C, Gatto-Cardia C, Ortega F, Huertas F et al.
578 Efficacy of Biodanza for Treating Women with Fibromyalgia. *The Journal of Alternative and*
579 *Complementary Medicine*. 2010;16(11):1191-1200.
- 580 55. Carbonell-Baeza A, Aparicio V, Sjöström M, Ruiz J, Delgado-Fernández M. Pain and Functional
581 Capacity in Female Patients with fibromyalgia. *Pain Medicine*. 2011;12(11):1667-1675.
- 582 56. Carbonell-Baeza A, Romero A, Aparicio V, Ortega F, Tercedor P, Delgado-Fernández M et al.
583 Preliminary Findings of a 4-Month Tai Chi Intervention on Tenderness, Functional Capacity,
584 Symptomatology, and Quality of Life in Men With Fibromyalgia. *American Journal of Men's*
585 *Health*. 2011;5(5):421-429.
- 586 57. Carbonell-Baeza A, Ruiz J, Aparicio V, Ortega F, Delgado-Fernández M. The 6-Minute Walk Test in
587 Female Patients with fibromyalgia: Relationship With Tenderness, Symptomatology, Quality of
588 Life, and Coping Strategies. *Pain Management Nursing*. 2013;14(4):193-199.
- 589 58. Carbonell-Baeza A, Álvarez-Gallardo I, Segura-Jiménez V, Castro-Piñero J, Ruiz J, Delgado-
590 Fernández M et al. Reliability and Feasibility of Physical Fitness Tests in Female Patients with
591 fibromyalgia. *International Journal of Sports Medicine*. 2014;36(02):157-162.
- 592 59. Cardoso FS, Curtolo M, Natour J, Lombardi Júnior I. Assessment of quality of life, muscle strength
593 and functional capacity in women with fibromyalgia. *Rev Bras Reumatol*. 2011;51(4):344-350.
- 594 60. Córdoba-Torrecilla S, Aparicio V, Soriano-Maldonado A, Estévez-López F, Segura-Jiménez V,
595 Álvarez-Gallardo I et al. Physical fitness is associated with anxiety levels in women with
596 fibromyalgia: the al-Ándalus project. *Quality of Life Research*. 2015;25(4):1053-1058.
- 597 61. Ericsson A, Bremell T, Mannerkorpi K. Usefulness of multiple dimensions of fatigue in
598 fibromyalgia. *Journal of Rehabilitation Medicine*. 2013;45(7):685-693.

- 599 62. Ernberg M, Christidis N, Ghafouri B, Bileviciute-Ljungar I, Löfgren M, Bjersing J et al. Plasma
600 Cytokine Levels in Fibromyalgia and Their Response to 15 Weeks of Progressive Resistance
601 Exercise or Relaxation Therapy. *Mediators of Inflammation*. 2018;2018:1-14.
- 602 63. Giannotti E, Koutsikos K, Pigatto M, Rampudda M, Doria A, Masiero S. Medium-/Long-Term
603 Effects of a Specific Exercise Protocol Combined with Patient Education on Spine Mobility,
604 Chronic Fatigue, Pain, Aerobic Fitness and Level of Disability in Fibromyalgia. *BioMed Research
605 International*. 2014;2014:1-9.
- 606 64. Hernando-Garijo I, Ceballos-Laita L, Mingo-Gómez MT, Medrano-de-la-Fuente R, Estébanez-de-
607 Miguel E, María Martínez-Pérez N, Jiménez-Del-Barrio S. Immediate Effects of a Telerehabilitation
608 Program Based on Aerobic Exercise in Women with Fibromyalgia. *Int J Environ Res Public Health*.
609 2021 Feb 20;18(4):2075. doi: 10.3390/ijerph18042075.
- 610 65. Homann D, Stefanello J, Góes S, Leite N. Redução da capacidade funcional e exacerbação da dor
611 durante o esforço do teste de caminhada de 6 minutos em mulheres com fibromialgia. 2018.
- 612 66. Mannerkorpi K, Nordeman L, Cider Å, Jonsson G. Does moderate-to-high intensity Nordic walking
613 improve functional capacity and pain in fibromyalgia? A prospective randomized controlled trial.
614 *Arthritis Research & Therapy*. 2010;12(5):R189.
- 615 67. Mingorance JA, Montoya P, García Vivas Miranda J, Inmaculada Riquelme I. A Comparison of the
616 Effect of Two Types of Whole Body Vibration Platforms on Fibromyalgia. A Randomized
617 Controlled Trial. *Int J Environ Res Public Health*. 2021 Mar 15;18(6):3007. doi:
618 10.3390/ijerph18063007.
- 619 68. Ollevier A, Vanneuville I, Carron P, Baetens T, Goderis T, Gabriel L, Van de Velde D. A 12-week
620 multicomponent therapy in fibromyalgia improves health but not in concomitant moderate
621 depression, an exploratory pilot study. *Disabil Rehabil*. 2020 Jun;42(13):1886-1893. doi:
622 10.1080/09638288.2018.1543361.
- 623 69. Polat M, Abdulvahap Kahveci A, Birsen Muci B, Zafer Günendi Z, Gülçin Kaymak Karataş G. The
624 Effect of Virtual Reality Exercises on Pain, Functionality, Cardiopulmonary Capacity, and Quality
625 of Life in Fibromyalgia Syndrome: A Randomized Controlled Study. *Games Health J*. 2021
626 Jun;10(3):165-173. doi: 10.1089/g4h.2020.0162.
- 627 70. Salvat I, Zaldivar P, Monterde S, Montull S, Miralles I, Castel A. Functional status, physical activity
628 level, and exercise regularity in patients with fibromyalgia after Multidisciplinary treatment:
629 retrospective analysis of a randomized controlled trial. *Rheumatology International*.
630 2016;37(3):377-387.

- 631 71. Sañudo B, Galiano D, Carrasco L, Blagojevic M, de Hoyo M, Saxton J. Aerobic Exercise Versus
632 Combined Exercise Therapy in Women With Fibromyalgia Syndrome: A Randomized Controlled
633 Trial. *Archives of Physical Medicine and Rehabilitation*. 2010;91(12):1838-1843.
- 634 72. Soriano-Maldonado A, Amris K, Ortega F, Segura-Jiménez V, Estévez-López F, Álvarez-Gallardo I
635 et al. Association of different levels of depressive symptoms with symptomatology, overall
636 disease severity, and quality of life in women with fibromyalgia. *Quality of Life Research*.
637 2015;24(12):2951-2957.
- 638 73. Soriano-Maldonado A, Henriksen M, Segura-Jiménez V, Aparicio V, Carbonell-Baeza A, Delgado-
639 Fernández M et al. Association of Physical Fitness With Fibromyalgia Severity in Women: The al-
640 Ándalus Project. *Archives of Physical Medicine and Rehabilitation*. 2015;96(9):1599-1605.
- 641 74. Tavares L, Germano Maciel D, Pereira Barros da Silva T, Brito Vieira W. Comparison of functional
642 and isokinetic performance between healthy women and women with fibromyalgia. *Journal of*
643 *Bodywork and Movement Therapies*. 2020;24(1):248-252.
- 644 75. Villafaina S, Borrega-Mouquinho Y, Fuentes-García J, Collado-Mateo D, Gusi N. Effect of Exergame
645 Training and Detraining on Lower-Body Strength, Agility, and Cardiorespiratory Fitness in
646 Women with Fibromyalgia: Single-Blinded Randomized Controlled Trial. *International Journal of*
647 *Environmental Research and Public Health*. 2019;17(1):161.
- 648 76. Vincent A, Whipple M, Low P, Joyner M, Hoskin T. Patients With Fibromyalgia Have Significant
649 Autonomic Symptoms But Modest Autonomic Dysfunction. *PM&R*. 2016;8(5):425-435.
- 650 77. Silva A, Chagas D, Cavaliere M, Pinto S, de Oliveira Barbosa J, Batista L. Kinematic analysis of
651 subtalar eversion during gait in women with fibromyalgia. *The Foot*. 2016;28:42-46.
- 652 78. Góes S, Leite N, de Souza R, Homann D, Osiecki A, Stefanello J et al. Características da marcha de
653 mulheres com fibromialgia: um padrão prematuro de envelhecimento. *Revista Brasileira de*
654 *Reumatologia*. 2014;54(5):335-341.
- 655 79. Auvinet B, Chaleil D. Identification of subgroups among patients with fibromyalgia. *Reumatismo*.
656 2012;64(4).
- 657 80. Shigetoh H, Tanaka Y, Koga M, Osumi M, Morioka S. The Mediating Effect of Central Sensitization
658 on the Relation between Pain Intensity and Psychological Factors: A Cross-Sectional Study with
659 Mediation Analysis. *Pain Research and Management*. 2019;2019:1-6.
- 660 81. Lundin-Olsson L, Nyberg L, Gustafson Y. "Stops walking when talking" as a predictor of falls in
661 elderly people. *Lancet*. 1997;349:617.

662 82. Eyskens J, Nijs J, Wouters K, Moorkens G. Reduced gait automaticity in female patients with
663 chronic fatigue syndrome: Case-control study. *Journal of Rehabilitation Research and*
664 *Development*. 2015;52(7):805-814.

665 83. Rolland Y, Lauwers-Cances V, Cournot M, Nourhashémi F, Reynish W, Rivière D, et al. Sarcopenia,
666 calf circumference, and physical function of elderly women: a cross-sectional study. *J Am Geriatr*
667 *Soc*. 2003;51:1120-4.

668 84. Laurentani F, Russo C, Bandinelli S, Bartali B, Cavazzini C, Di Iorio A, Corsi AM, Rantanen T,
669 Guralnik JM, Ferrucci L. Age-associated changes in skeletal muscles and their effect on mobility:
670 an operational diagnosis of sarcopenia. *J Appl Physiol*. 2003;95:1851-60.

671 85. Kamiya K, Hamazaki N, Matsue Y, Mezzani A, Corrà U, Matsuzawa R, Nozaki K, Tanaka S, Maekawa
672 E, Noda C, Yamaoka-Tojo M, Matsunaga A, Masuda T, Ako J. Gait speed has comparable prognostic
673 capability to six-minute walk distance in older patients with cardiovascular disease. *European*
674 *Journal of Preventive Cardiology*. 2017;25(2):212-219.

675 86. Roshanravan B, Robinson-Cohen C, Patel K, Ayers E, Littman A, de Boer I, Ickler TA, Himmelfarb
676 J, Katzell LI, Kestenbaum B, Seliger S. Association between Physical Performance and All-Cause
677 Mortality in CKD. *Journal of the American Society of Nephrology*. 2013;24(5):822-830.

678 87. Studenski S. Gait Speed and Survival in Older Adults. *JAMA*. 2011;305(1):50.

679 88. Mannerkorpi K, Svantesson U, Broberg C. Relationships Between Performance-Based Tests and
680 Patients' Ratings of Activity Limitations, Self-Efficacy, and Pain in Fibromyalgia. *Archives of*
681 *Physical Medicine and Rehabilitation*. 2006;87(2):259-264.

682 89. Cohen, Jacob (1988). *Statistical Power Analysis for the Behavioral Sciences*. Routledge. ISBN 978-
683 1-134-74270-7.

684 90. Auvinet B, Bileckot R, Alix A, Chaleil D, Barrey E. Gait disorders in patients with fibromyalgia. *Joint*
685 *Bone Spine*. 2006;73(5):543-546.

686 91. Jones J, Rutledge D, Jones K, Matallana L, Rooks D. Self-Assessed Physical Function Levels Of
687 Women with Fibromyalgia. *Women's Health Issues*. 2008;18(5):406-412.

688 92. Pierrynowski MP, Tiidus PP, Galea V. Women with fibromyalgia walk with an altered muscle
689 synergy. *Gait Posture*. 2005 Nov;22(3):210-8. doi: 10.1016/j.gaitpost.2004.09.007.

690 93. Kaleth A, Slaven J, Ang D. Determining the Minimal Clinically Important Difference for 6-Minute
691 Walk Distance in Fibromyalgia. *American Journal of Physical Medicine & Rehabilitation*.
692 2016;95(10):738-745.

- 693 94. Yogev-Seligmann G, Giladi N, Gruendlinger L, Hausdorff JM The contribution of postural control
694 and bilateral coordination to the impact of dual tasking on gait. *Exp Brain Res*. 2013
695 Apr;226(1):81-93. doi: 10.1007/s00221-013-3412-9.
- 696 95. Hagner-Derengowska M, Krystian Kałużny K, Hagner W, Kałużna A, Kochański B, Borkowska
697 A, Budzyński J. Gait Parameters during Dual Tasks in Healthy Postmenopausal Women. *Biomed*
698 *Res Int*. 2016;2016:1205469. doi: 10.1155/2016/1205469.
- 699 96. Bell T, Trost Z, T Buelow M, Olivio Clay O, Younger J, Moore D, Crowe M. Meta-analysis of
700 cognitive performance in fibromyalgia. *J Clin Exp Neuropsychol*. 2018 Sep;40(7):698-714.
701 doi:10.1080/13803395.2017.1422699.
- 702 97. Núñez-Fuentes D, Obrero-Gaitán E, Zagalaz-Anula N, Ibáñez-Vera AJ, Achalandabaso-Ochoa A,
703 López-Ruiz MC, Rodríguez-Almagro D, Lomas-Vega R. Alteration of Postural Balance in Patients
704 with Fibromyalgia Syndrome-A Systematic Review and Meta-Analysis. 2021 Jan 15;11(1):127.
705 doi: 10.3390/diagnostics11010127.
- 706 98. Kim D Jones, Laurie A King, Scott D Mist, Robert M Bennett, Fay B Horak Postural control deficits
707 in people with fibromyalgia: a pilot study. *Arthritis Res Ther*. 2011 Aug 2;13(4):R127. doi:
708 10.1186/ar3432.
- 709 99. Collado-Mateo D, Gallego-Diaz JM, Adsuar JC, Domínguez-Muñoz FJ, P R Olivares PR, Gusi N. Fear
710 of Falling in Women with Fibromyalgia and Its Relation with Number of Falls and Balance
711 Performance. *Biomed Res Int*. 2015;2015:589014. doi: 10.1155/2015/589014.

Tables

Table 1: evaluation of the selected documents using the NOS scale.

STUDY	Selection				Comparability		Outcome		Total
	1	2	3	4	1a	2b	1	2	
Akkaya N et al, 2012 ^[48] .	*			**	*	*	*	*	7
Andreissy Breda C et al, 2013 ^[49] .	*			**	*	*	*	*	8
Aparicio V et al, 2015 ^[50] .	*		*	**	*	*	*	*	8
Auvinet B et al, 2011 ^[51]	*	*		**	*	*	*	*	8
Ayán C et al, 2007 ^[52] .	-		*	**	*	*	*	*	7
Carbonell-Baeza A et al, 2010 ^[53] .	*			**	*	*	*	*	6
Carbonell-Baeza A et al, 2010 ^[54] .	*			**	*	*	*	*	6
Carbonell-Baeza A et al, 2011 ^[55] .	*			**	-	-	-	-	3
Carbonell-Baeza A et al, 2011 ^[56] .	*			**	-	-	-	-	3
Carbonell-Baeza A et al, 2013 ^[57] .	*			**	-	-	-	-	3
Carbonell-Baeza A et al, 2014 ^[58] .	*			**	-	-	-	-	3
Cardoso FS et al, 2018 ^[59] .	*		*	**	*	*	*	*	8
Córdoba-Torrecilla S et al, 2015 ^[60] .	*			**	-	-	-	*	4
Ericsson A et al, 2013 ^[61] .	*		*	**	*	*	*	*	8
Ernberg M et al, 2018 ^[62] .	*		*	**	*	*	*	*	8
Giannotti E et al, 2014 ^[63] .	*			**	*	*	*	*	7
Góes S et al, 2015 ^[41] .	*		*	**	*	*	*	*	8
Heredia Jiménez J et al, 2009 ^[42] .	*		*	**	*	*	*	*	8
Heredia-Jimenez J et al, 2013 ^[43] .	*		*	**	*	*	*	*	8
Heredia-Jimenez J et al, 2016 ^[44] .	*		*	*	*	*	*	*	7
Hernando-Garijo I et al, 2021 ^[64]	*	*	*	**	*	*	*	*	9
Homann D et al, 2011 ^[65] .	*			**	*	*	*	*	7
Koca I et al, 2015 ^[45] .	*		*	**	*	*	*	*	8
Latorre-Román P et al, 2014 ^[46] .	*		*	**	*	*	*	*	8
Mannerkorpi K et al 2010 ^[66] .	*	*	*	**	*	*	*	*	9
Martín-Martínez J et al, 2020 ^[47] .	*			**	*	*	*	*	5
Mingorance J et al, 2021 ^[67]	*	*		**	*	*	-	*	7
Ollevier A, et al, 2019 ^[68]	-	*		**	-	-	*	*	5
Polat M et al, 2021 ^[69] .	*		*	**	*	*	*	*	8
Salvat I et al, 2016 ^[70] .	*		*	**	*	*	**	*	9
Sañudo B et al, 2010 ^[71] .	*	*	*	**	*	*	**	*	10
Soriano-Maldonado A et al, 2015 ^[72] .	*			**	*	*	*	*	7
Soriano-Maldonado A et al, 2015 ^[73] .	*			**	*	*	**	*	3
Tavares L et al, 2020 ^[74] .	*			**	*	*	**	*	8
Villafaina S et al, 2019 ^[75] .	*	*		**	*	*	**	*	9
Vincent A et al, 2016 ^[76] .	*		*	**	*	*	*	*	8

Formatted: Portugues(Brazil)

Formatted: Portugues(Brazil)

Formatted: Portugues(Brazil)

Formatted: Portugues(Brazil)

732

733

734




Table 2. Results of the 6-minute walk test.

Study	N [N (Women%)]	n	Age (SD)	Weight [(Kg) (SD)]	Height [(Cm) (SD)]	BMI [(Kg/m ²) (SD)]	Results (m)
Akkaya N et al, 2012 ^[42]	92 (100%)	FM 51	35.5 (9.9)	-	-	27.0 (4.2)	300.9 (52.3)*
		HC 41	33.3 (7.4)	-	-	26.3 (3.9)	373.9 (50.5)*
Andreissy Breda C et al, 2013 ^[43]	58 (100%)	FM 30	42.6 (5.8)	72.4 (9.3)	158.9 (5.3)	28.7 (3.9)	441.8 (84.1)*
		HC 28	40.7 (6.3)	70.6 (13.1)	160.7 (6.3)	27.2 (5.1)	523.9 (80.3)*
Aparicio V et al, 2015 ^[44]	737 (100%)	FM 487	51.9 (8.3)	71.3 (14.0)	157.8 (6.0)	28.6 (5.4)	483.5 (89.6)*
		HC 250	49.3 (9.9)	67.8 (12.7)	159.8 (6.2)	26.5 (4.6)	586.3 (73.3)*
Ayán C et al, 2007 ^[45]	29 (100%)	FM 29	53 (9)	-	-	26 (4)	432.8 (61.2)
Carbonell-Baeza A et al, 2010 ^[46]	65 (100%)	FM1 33	51.4 (7.4)	71.2 (2.1)	-	28.5 (0.9)	451.9 (14.0)
		FM2 32	50.0 (7.3)	68.1 (2.2)	-	27.8 (0.9)	458.7 (15.0)
Carbonell-Baeza A et al, 2010 ^[47]	59 (100%)	FM1 27	54.2 (6.2)	68.1 (2.2)	-	27.5 (0.9)	448.7 (13.5)
		FM2 32	51.4 (7.4)	68.5 (2.1)	-	28.2 (0.9)	456.6 (12.7)
Carbonell-Baeza A et al, 2011 ^[48]	123 (100%)	FM 123	51.7 (7.2)	70.75 (13.66)	157.26 (4.97)	28.54 (5.60)	447.02 (83.54)
Carbonell-Baeza A et al, 2011 ^[49]	6 (0%)	FM 6	52.3 (9.3)	79.3 (10.7)	-	27.1 (3.8)	495.8 (78.0)
Carbonell-Baeza A et al, 2013 ^[50]	118 (100%)	FM 118	51.9 (7.3)	-	-	28.58 (5.6)	438.72
Carbonell-Baeza A et al, 2014 ^[52]	100 (100%)	FM 100	50.6 (8.6)	70.4 (12.5)	158.6 (5.9)	28.0 (5.4)	473.11 (81.74)
Cardoso FS et al, 2018 ^[53]	31 (100%)	FM 16	53.5 (7.5)	70.6 (14.6)	158 (5)	28.0 (4.9)	446.7 (126.0)*
		HC 15	54.1 (4.4)	70.6 (13.7)	160 (9)	27.5 (4.5)	522.1 (47.6)*
Córdoba-Torrecilla S et al, 2015 ^[54]	439 (100%)	FM 439	52.2 (8.0)	71.3 (14.0)	157.8 (6.0)	28.6 (5.5)	484.0 (81.7)
Ericsson A et al, 2013 ^[55]	133 (100%)	FM 133	46 (8.6)	-	-	27.3 (5.3)	507.0 (84.0)
Emberg Met et al, 2018 ^[56]	255 (100%)	FM 125	51.2 (9.4)	-	-	28.0 (5.2)	551.4 (71.0)*
		HC 130	48.2 (11.4)	-	-	24.2 (3.8)	656.9 (60.1)*
Giannotti E et al, 2014 ^[57]	32 (93,75%)	FM1 20	52.8 (10.6)	-	-	24.3 (3.4)	378 (68.4) ^p
		FM2 12	51.3 (6.3)	-	-	23.4 (4.2)	403.2 (86.4) ^p
Hernando-Garjón I et al, 2021 ^[64]	34	FM1 17	51.81 (9.05)	68.19 (16.88)	158.63 (6.29)	27.25 (7.30)	403.57 (107.13)

Formatted: Portuguese(Brazil)

Formatted: Portuguese(Brazil)

	(100%)	FM2 17	55.06 (8.51)	68.13 (15.10)	161.81 (5.13)	25.93 (5.27)	407.01 (137.09)
Homann D et al, 2011 ^[58]	39 (100%)	FM 20	39.50 (6.07)	70.97 (14.39)	159.38 (6.48)	27.69 (5.43)	473.52 (77.84)*
		HC 19	41.84 (6.18)	72.04 (9.64)	159.34 (5.15)	28.40 (3.89)	541.75 (85.62)*
Latorre-Román P et al, 2014 ^[40]	50 (100%)	FM 36	49.8 (5.4)	67.2 (12.1)	157 (4)	27.7 (4.8)	477.5 (63.1)*
		HC 14	47.3 (5.9)	65.6 (8.7)	159 (6)	25.9 (3.2)	561.5 (73.1)*
Mannerkorpi K et al, 2010 ^[59]	33 (100%)	FM 33	50 (7.6)	-	-	28 (4.5)	522 (56.1)
Mingorance J et al, 2021 ^[67]	60 (90%)	FM1	50.25 (8.53)	67.00 (7.46)	169.15 (6.41)	23.34 (1.23)	391.25 (21.9)
		FM2	52.30 (8.04)	65.05 (5.82)	168.25 (6.35)	22.95 (1.30)	365 (11)
		FM3	54.85 (8.62)	67.00 (7.43)	166.90 (7.86)	24.21 (3.93)	385 (31.85)
Ollevier A et al, 2019 ^[68]	46 (100%)	FM1	40.76 (6.62)	69.76 (16.71)	1.66 (0.06)	25.30 (5.12)	328.91 (98.12)
Polat M et al, 2021 ^[69]	40 (100%)	FM1 20	47.0 (7.1)	71.4 (10.1)	160.0 (5.5)	27.9 (0.80)	443.15 (109.2)
		FM2 20	42.6 (8.7)	69.7 (8.03)	162.0 (6.6)	26.6 (0.79)	467 (43.9)
Salvat I et al, 2016 ^[70]	155 (100%)	FM1 81	50.0	-	-	26.3	384.0
		FM2 74	50.0	-	-	27.9	353.0
Sañudo B et al, 2010 ^[71]	64 (100%)	FM1 22	55.9 (1.6)	72.3 (2.3)	157 (1)	29.6 (1.1)	512.5 (15.9)
		FM2 21	55.9 (1.7)	68.5 (3.0)	157 (2)	27.6 (1.1)	535.0 (16.2)
		FM3 21	56.6 (1.9)	74.5 (3.3)	158 (1)	29.7 (1.1)	488.7 (16.9)
Soriano-Maldonado A et al, 2015 ^[72]	451 (100%)	FM 451	52.0	-	-	28.6	486.3 (3.71)
Soriano-Maldonado A et al, 2015 ^[73]	444 (100%)	FM 444	52.1 (7.9)	-	-	28.5 (5.2)	486 (79)
Tavares L et al, 2020 ^[74]	40 (100%)	FM 20	40.55 (6.19)	62.42 (7.80)	1.60 (0.05)	24.40 (2.58)	546.40 (60.88)*
		HC 20	38.7 (7.30)	63.75 (7.56)	1.61 (0.06)	24.70 (3.29)	616.39 (48.05)*
Villafaina S et al, 2019 ^[75]	37 (100%)	FM1 22	54.27 (9.29)	-	-	27.11 (2.90)	491.15 (80.21)
		FM2 15	53.44 (9.47)	-	-	28.19 (3.88)	517.45 (58.42)
Vincent A et al, 2016 ^[76]	60 (100%)	FM 30	47.0 (10.4)	-	-	25.8 (4.6)	570.7 (51.9)*
		HC 30	41.1 (8.4)	-	-	26.0 (4.0)	640.2 (65.7)*

FM= Fibromyalgia syndrome; P = Data obtained indirectly; BMI = Body mass index; HC = Healthy control group; FMx = Fibromyalgia subgroup; *P<0.05.

Formatted: Portuguese(Brazil)

Formatted: Portuguese(Brazil)

Table 3. Results of the 8 foot up and go test

Study	N (Women%)	n	Age (SD)	Weight (Kg) (SD)	Height (Cm) (SD)	Body mass index (Kg/m ²) (SD)	Results 8UG Test (s) (Differences between groups)
Aparicio V et al, 2015 ^[50] .	737 (100%)	FM 487	51.9 (8.3)	71.3 (14.0)	157.8 (6.0)	28.6 (5.4)	7.02 (2.34)*
		HC 250	49.3 (9.9)	67.8 (12.7)	159.8 (6.2)	26.5 (4.6)	5.27 (1.03)*
Carbonell-Baeza A et al, 2010 ^[54] .	65 (100%)	FM1 33	51.4 (7.4)	71.2 (2.1)	-	28.5 (0.9)	8.5 (0.4)
		FM2 32	50.0 (7.3)	68.1 (2.2)	-	27.8 (0.9)	8.2 (0.4)
Carbonell-Baeza A et al, 2010 ^[55] .	59 (100%)	FM1 27	54.2 (6.2)	68.1 (2.2)	-	27.5 (0.9)	7.6 (0.3)
		FM2 32	51.4 (7.4)	68.5 (2.1)	-	28.2 (0.9)	8.3 (0.3)
Carbonell-Baeza A et al, 2011 ^[56] .	123 (100%)	FM 123	51.7 (7.2)	70.75 (13.66)	157.26 (4.97)	28.54 (5.60)	8.35 (2.32)
Carbonell-Baeza A et al, 2011 ^[57] .	6 (0%)	FM 6	52.3 (9.3)	79.3 (10.7)	-	27.1 (3.8)	6.8 (1.1)
Carbonell-Baeza A et al, 2014 ^[58] .	100 (100%)	FM 100	50.6 (8.6)	70.4 (12.5)	158.6 (5.9)	28.0 (5.4)	7.31 (2.37)

FM= Fibromyalgia syndrome; **HC** = Healthy control group; **FMx** = Fibromyalgia subgroup; *= P<0.05.

Table 4. Characteristics and results of studies that analyze gait pattern characteristics.

Study	N (Women%)	n	Age (SD)	Weight (Kg) (SD)	Height (Cm) (SD)	Body mass index (Kg/m ²) (SD)	Test	System	Stride Length (m)	Cadence (step/min)	Swing (%cycle)	Stance (%cycle)	Single support (%cycle)	Double support (%cycle)
Auvinet B et al, 2011 ^[51]	104 (100%)	FM 52	44.1 (8.1)	-	165 (5.8)	24.2 (4.1)	40 meters	Locometrix™ (three accelerometers, recording device)	■	■	■	■	■	■
		HC 52	44.5 (7.3)	-	164 (6.4)	23.8 (4.4)			■	■	■	■	■	■
Góes S et al, 2015 ^[41]	32 (100%)	FM 16	41.5 (5.9)	-	-	28.2 (3.9)	Walking speed	Vicon; MX-13 (6- camera Vicon motion analysis system)	1.22 (0.09)	58.42 (4.52)	■	■	■	■
		HC 16	40.4 (6.4)	-	-	26.8 (5.6)			1.23 (0.09) (P= 0.755)	57.41 (4.31) (P= 0.523)	■	■	■	■
Heredia Jiménez J et al, 2009 ^[42]	99 (100%)	FM 55	49.5 (8.9)	69.2 (12.9)	157.9 (6.6)	27.8 (5.1)	18.6m walkway	GAITRite system; CIR Systems Inc, Clifton, NJ, USA	1.19 (0.14)	109.5 (12.6)	36.6 (2.2)	63.4 (2.2)	36.6 (2.2)	26.7 (4.5)
		HC 44	47.1 (6.8)	67.8 (13.4)	157.0 (5.4)	27.3 (5.3)			1.33 (0.11) (P= 0.001)	124.8 (8.5) (P= 0.001)	39.0 (1.4) (P= 0.001)	60.9 (1.4) (P= 0.001)	39.0 (1.4) (P= 0.001)	22.1 (2.8) (P= 0.001)
Heredia-Jimenez J et al, 2013 ^[43]	26 (0%)	FM 12	45.8 (7.4)	81.1 (7.8)	173.3 (5.2)	27.0 (2.4)	18.6m walkway	GAITRite system; CIR Systems Inc, Clifton, NJ, USA	1.37 (0.15)	101.4 (11.8)	36.6 (1.3)	63.4 (1.3)	36.6 (1.3)	30.0 (2.5)
		HC 14	44.4 (7.2)	81.9 (13.1)	173.9 (5.5)	27.0 (4.0)			1.54 (0.11) (P= 0.002)	112.9 (7.6) (P= 0.008)	37.3 (1.4) (P= 0.218)	62.6 (1.4) (P= 0.212)	37.3 (1.4) (P= 0.218)	25.3 (3.0) (P= 0.158)
Heredia-Jimenez J et al, 2016 ^[44]	115 (100%)	FM 65	49.3 (8.7)	69.1 (11.3)	157.1 (6.2)	27.8 (4.1)	18.6m walkway	GAITRite system; CIR Systems Inc, Clifton, NJ, USA	2.9 (1.4)	■	■	■	■	■
		HC 50	47.4 (6.2)	68.7 (12.4)	157.4 (5.9)	27.3 (5.1)			2.4 (0.9) (P= 0.04)	■	■	■	■	■
Koca I et al, 2015 ^[45]	120 (100%)	FM 82	40.7 (2.0)	-	-	26.2 (4.2)	Walking speed	Not described	■	■	■	■	■	■
		HC 38	38.8 (2.8)	-	-	25.1 (2.1)			■	■	■	■	■	■
Latorre-Román P et al, 2014 ^[46]	50 (100%)	FM 36	49.8 (5.4)	67.2 (12.1)	157 (4)	27.7 (4.8)	6MWT	GAITRite system; CIR Systems Inc, Clifton, NJ, USA	1.36 (0.12)	178.9 (29.8)	■	■	■	■
		HC 14	47.3 (5.9)	65.6 (8.7)	159 (6)	25.9 (3.2)			1.50 (0.14) (P=0.001)	201.3 (59.6) (P=0.03)	■	■	■	■
Martín-Martínez J et al, 2020 ^[47]	36 (100%)	FM 36	54.6 (10.2)	-	-	27.29 (4.89)	10- MWT	Functional Assessment of Biomechanics™ (FAB) System (Biosyn System Inc; Surrey, BC, Canada)	1.35 (0.21)	135.6 (21)	■	■	■	■
Mingorance J et al, 2021 ^[67]	60 (90%)	FM1	50.25 (8.53)	67.00 (7.46)	169.15 (6.41)	23.34 (1.23)	6MWT Walking speed	CvMob 3.1 and CasioExilimEX-FS10 camera	■	■	31.52 (3.44)	61.48 (3.43)	■	■
		FM2	52.30 (8.04)	65.05 (5.82)	168.25 (6.35)	22.95 (1.30)			■	■	31.77 (1.99)	64.75 (7.24)	■	■
		FM3	54.85 (8.62)	67.00 (7.43)	166.90 (7.86)	24.21 (3.93)			■	■	31.69 (2.78)	68.30 (2.77)	■	■

FM= Fibromyalgia syndrome; HC= Healthy control group